Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer

Ardelyx
Posted on: 25 Oct 16

FREMONT, Calif., Oct. 24, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Reginald Seeto, MBBS, has joined the company in the newly created position of chief operating officer. Dr. Seeto brings over a decade of pharmaceutical industry experience in corporate development, strategic operations and global marketing to Ardelyx. His appointment is effective immediately.

"We could not be more excited about the addition of Reg to our executive leadership team," said Mike Raab, president and chief executive officer of Ardelyx. "As we continue to advance our programs through the clinic, led by the multiple ongoing Phase 3 studies for tenapanor, and start to prepare for commercialization, Reg's track record of successfully introducing new therapies and delivering those therapies to patients, along with his expertise in corporate development, will be invaluable to our team. Reg achieved tremendous success in his years at AstraZeneca and MedImmune, and we look forward to building upon that success as he integrates into his role at Ardelyx."

Dr. Seeto brings to Ardelyx more than 13 years of experience in strategic corporate development and senior marketing roles at major global pharmaceutical companies. Prior to joining the company, he spent eight years in roles of increasing responsibility at AstraZeneca and MedImmune, the Biologics Division of AstraZeneca, most recently serving as vice president, head of partnering and strategy for AstraZeneca. Earlier, he served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune. Prior to joining AstraZeneca/MedImmune, Dr. Seeto held senior marketing roles at Organon Biosciences, which was acquired by Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals. Earlier, Dr. Seeto served as an engagement manager for McKinsey & Company and started his career as a practicing medical doctor and researcher in Australia. Dr. Seeto has published several publications in peer-reviewed journals, including publications focused on his work in gastrointestinal research. Dr. Seeto earned both his B.S. and MBBS in medical studies from the University of Sydney, Australia.

"I am delighted to join the Ardelyx team at such an exciting time for the company as they progress through the late-stage clinical development process for tenapanor and look to enter Phase 3 for RDX227675," said Dr. Seeto. "Ardelyx has a seasoned senior leadership team and an impressive clinical and preclinical pipeline, which were key drivers in my decision to join the company. I look forward to helping them bring new GI and cardio-renal therapies to patients in an area where there are very limited, effective treatments."

About Ardelyx, Inc.

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is developing RDX227675, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, a problem prevalent in patients with kidney and heart disease. Ardelyx is also advancing several research programs focused in GI and cardio-renal diseases. Ardelyx is located in Fremont, Calif. For more information, please visit Ardelyx's website at www.ardelyx.com.

For more information:
www.ardelyx.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.